DreamPharm Products:
Research Resources:
Alopecia, hair loss abstracts ||
Arch Immunol Ther Exp (Warsz). 2002;50(5):333-6.
The protective role of the HLA-DR locus in patients with various clinical types of alopecia areata.
Broniarczyk-Dyla G, Prusinska-Bratos M, Dubla-Berner M, Arkuszewska C, Borowiec M, Kowalski ML, Woszczek G.
Department and Clinic of Dermatology and Venereology, Medical University of Lodz.
One of the genetic factors associated with the development of alopecia areata (AA) is the HLA locus. The study comprised 52 patients with AA aged 10 to 64 years. The frequences of HLA-DRB alleles in the patients and controls were compared. The control group comprised 152 healthy persons. Familial occurrence of AA was seen in 7 (13.5%) cases. A significantly lower frequency of HLA-DRB1*03 was observed in patients with AA comparison with the control group. In all patients with AA, alleles HLA-DRB1*15/*16 occurred more frequently than in the control group, but this was not significant after correction. In the group of patients with more severe forms of alopecia areata (alopecia areata totalis/alopecia areata universalis) there was no significant difference in HLA-DR allele distribution.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12455867&dopt=Abstract
Gan To Kagaku Ryoho. 2002 Jul;29(7):1147-52.
[Clinical evaluation of effects from neo-adjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer]
[Article in Japanese]
Tong F, Zhou B, Yang D, Cao Y, Liu P, Liu H, Qiao X, Zhang J.
Dept. of 4th Surgery and Breast Disease Research Center, People's Hospital, Beijing University Medical School.
Neo-adjuvant chemotherapy of epirubicin plus paclitaxel was administered to 23 patients with locally advanced breast cancer (including 13 cases of stage IIb, 6 of stage IIIa, and 4 of stage IIIb). All patients were female. They were treated with epirubicin 60 mg/m2, on day 1, by i.v. followed paclitaxel 150 mg/m2 by 3 hours continuous infusion on day 2 and every 3 weeks repeatedly. Premedication with dexamethasone, ondansetron, diphenhydramine and cimetidine were administered to prevent gastroenteric and allergic reactions before chemotherapy. Two to 4 cycles were used. Ten out of 23 patients had a complete response, 10 had partial response, and 3 had no change. The response rate was 87% (20/23). Six out of 23 patients underwent breast conserving surgery as tumor size had become smaller and downstaging was realized after neo-adjuvant chemotherapy. The major toxicities included neutropenia, myalgia, arthralgia, nephrotoxicity, gastroenteric reactions, alopecia and flushing to the face. However, these were well tolerated in these patients.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12145994&dopt=Abstract
Laryngoscope. 2002 Jun;112(6):962-7.
Ectodermal dysplasia: otolaryngologic manifestations and management.
Daniel E, McCurdy EA, Shashi V, McGuirt WF Jr.
Department of Otolaryngology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. edaniefubmc.edu
OBJECTIVE: To present the otolaryngologic manifestations and management of 12 patients with the rare presentation of ectodermal dysplasia. STUDY DESIGN: A retrospective chart review combined with a patient evaluation by the specialties of genetics, dermatology, dentistry, and otolaryngology. METHODS: A review of the head and neck manifestations of the spectrum ectodermal dysplasia was undertaken by a retrospective chart review performed at a tertiary care children's hospital combined with a multidisciplinary evaluation by specialties of genetics, dermatology, dentistry, and otolaryngology. RESULTS: All 12 patients had confirmed ectodermal dysplasia by genetic evaluation with strong familial manifestations of the spectrum. Seven of 12 patients presented with X-linked hypohidrotic ectodermal dysplasia. Three of these seven were femalepatients and presented with variable expression. Common otolaryngologic manifestations included eczematoid skin changes, unusual facies, hypodontia, sparse scalp hair, chronic infections (rhinitis, pharyngitis, otitis media), epistaxis, ocular drying with corneal injury, dysphagia, hearing loss, and dysphonia. Immune evaluation was normal. Nasal cilia were deficient. CONCLUSIONS: Ectodermal dysplasia is a rare syndrome with heterogeneous manifestations secondary to hypoplasia of the mucous glands of the upper aerodigestive tract and ectodermal abnormalities. The spectrum is marked byhypohidrosis, recurrent ocular infections, chronic rhinitis, hypodontia, dystrophic nails, alopecia, and atypical facies. The recognition of this syndrome allows early management of ocular, dental, infectious, and dermatologic concerns with a multidisciplinary approach to management. Direct otolaryngologic management includes ocular and oral lubrication, treatment of infectious complications, and intervention to prevent and address hearing loss.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12160292&dopt=Abstract
problems. Based on Chinese herbs, Hair Million is an alternative solution to the age-related
There is no singular scientific or alternative cure for hair loss and hair growth as the
biology of hair growth is a highly complicated phenomenon.
It is unknown how Hair Million stops hair loss,
and promotes hair restoration.
Some of the advantages of Hair Million: firstly, it is relatively inexpensive,
and secondly, it is made only of traditionally used safe and healthy herbs that promote hair growth
according to Chinese pharmacopoeia.
For scientifically proven prescription medication, check Buy Propecia Online.
Herbs and Pharmaceuticals Online||
Constipation relief, laxative, colon cleansing ||
Best Realtor in Glendale, California: Residential Home and Commercial Property ||
Related Web pages ||
Key Links ||
Buy DHEA Online ||